Home > Healthcare > Medical Devices > Diagnostic Devices > cystatin c assay market
Get a free sample of Cystatin C Assay Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Cystatin C Assay Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
The cystatin C assay industry is consolidated, with key players including, Roche Diagnostics Limited, Siemens Healthineers AG, Abbott Laboratories, Beckman Coulter (Danaher Corporation), and others dominating the market space. These companies focus on ongoing product innovation, geographical expansion, and partnerships to secure substantial market shares. For instance, in January 2021, Roche acquired GenMark, which is involved in the development and manufacturing of cystatin C assays. This acquisition strengthened Roche's position in the cystatin C assay industry and expanded its product portfolio.
Some of the eminent market participants operating in the cystatin C assay industry include:
Market size for cystatin C assay was USD 269.6 million in 2023 and is expected to reach USD 522.6 billion by 2032 due to the increasing prevalence of chronic kidney diseases and in the surging need for early diagnosis, monitoring, and kidney stone management worldwide.
Cystatin C assay industry size from the kits products segment recorded USD 116.8 million in 2023 and is expected to register an appreciable CAGR from 2024-2032 owing to their prominent role in providing laboratories and healthcare facilities with convenient and ready-to-use solutions.
U.S. industry size for cystatin C assay recorded USD 102.4 million in 2023 due to the advanced healthcare infrastructure, widespread access to cutting-edge diagnostic technologies, and the increasing prevalence of chronic kidney diseases in the region.
Siemens Healthineers AG, Abbott Laboratories, Beckman Coulter (Danaher Corporation), Thermo Fisher Scientific Inc, bioM